Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis
about
Endothelial dysfunction: the role of sterol regulatory element-binding protein-induced NOD-like receptor family pyrin domain-containing protein 3 inflammasome in atherosclerosisMMP-12 deficiency attenuates angiotensin II-induced vascular injury, M2 macrophage accumulation, and skin and heart fibrosisAnimal models of systemic sclerosis: their utility and limitations.Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosisInvolvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model.Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors.Origin of fibrosing cells in systemic sclerosis.Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis.Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathwaysAutoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.Geniposide inhibited endothelial-mesenchymal transition via the mTOR signaling pathway in a bleomycin-induced scleroderma mouse model.Cellular transitions and tissue engineering.Do intravenous and subcutaneous angiotensin II increase blood pressure by different mechanisms?Animal models of scleroderma: current state and recent development.Adverse fibrosis in the aging heart depends on signaling between myeloid and mesenchymal cells; role of inflammatory fibroblasts.A vascular mechanistic approach to understanding Raynaud phenomenon.Double heterozygous mice for Klf5 and Fli1 genes: a new animal model of systemic sclerosis recapitulating its three cardinal pathological features.Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma.Recent advances in animal models of systemic sclerosis.Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.Pathogenesis of systemic sclerosis-current concept and emerging treatments.Modulation of angiotensin II signaling in the prevention of fibrosis.Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.Recovery of extracellular matrix components by enalapril maleate during the repair process of ultraviolet B-induced wrinkles in mouse skin.Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.Periostin in the pathogenesis of skin diseases.Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis.Early intervention by Captopril does not improve wound healing of partial thickness burn wounds in a rat model.Hypertension: a systemic key to understanding local keloid severity.Influence of the interaction between Ac‑SDKP and Ang II on the pathogenesis and development of silicotic fibrosis.A Potential Link Between Oxidative Stress and Endothelial-to-Mesenchymal Transition in Systemic Sclerosis
P2860
Q26852572-D2B14BAE-BFA7-424B-8D17-6CF225B7ADDCQ27339129-DFE02682-6471-44F2-9DA6-7E07ACAFD2D8Q28390528-FE864218-4400-4032-A49B-702F17E65F76Q33795658-AF7E0E6A-728C-422B-B72F-3D3867E71D5CQ33872629-DCE94E0B-9410-4EEF-B796-862AB385104CQ35755610-6616DEE2-3BFE-4A43-B506-F0D4757A90D1Q36264658-08E6918E-0AAC-45A4-96F1-ED18BB299730Q37395851-A4980193-A0D2-43AE-9609-13B8097BB8B4Q37620501-364675F7-98E7-45E5-ADA3-C03C7E1EA03AQ37689681-9B85AE28-8336-4339-907D-C46C8E9CC67AQ37732969-20877899-0C52-4351-8C7F-B2E2971BBDE1Q38095518-F4D024BB-A854-46AC-8486-78BA572D9A46Q38095579-848A59C9-4242-462E-8407-5569ABF89853Q38154834-80F31045-6A6A-4024-BB5A-7AE8351A7BF9Q38159348-7B7F5480-BFEA-4A43-B99E-6F44668A6E2AQ38299133-3C4AF6E8-18C7-4C2B-A13B-B20D18E4947EQ38489606-C1F42CB5-9DE0-41A9-9CF2-6F092ABF2BA8Q38681751-92D490B9-202B-494D-876C-EC381C7AE19DQ38701983-1952242C-0B65-469F-A53E-5080CD370E73Q38824987-11336395-B39D-43EC-BB11-34EFFEE69ADFQ39294794-2BF9DDAF-9286-418D-8F44-9BA4CE681159Q40362636-496325A0-84A0-4906-9959-DCE031F08689Q45965532-D612AF67-286A-4DBE-AC12-C1B0EC43193EQ47105256-448F20D7-A47F-4892-84D0-4971EC602983Q47718418-DCD719C4-ABBE-4E3F-8560-D4D3DB1DFDA5Q47792957-780BA81B-5818-42F8-A339-A7C4D9371DC8Q48179384-4BEAAC4D-C3A1-456B-BEA1-0E840C2F8991Q50070886-4C2CD136-6D70-479D-8D24-9E0AB254CAFAQ53599537-F917D4F2-2653-4F9B-9A49-69DAD32F627FQ55451084-5934C188-5547-4D8A-B37F-F1C9EC59CB29Q57072741-768BD496-AC3E-46C9-A416-B75965F27383
P2860
Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis
@ast
Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis
@en
type
label
Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis
@ast
Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis
@en
prefLabel
Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis
@ast
Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis
@en
P2093
P2860
P356
P1476
Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis
@en
P2093
Andreea M Bujor
Lukasz Stawski
Maria Trojanowska
P2860
P2888
P356
10.1186/AR4028
P50
P577
2012-08-22T00:00:00Z
P5875
P6179
1012115707